CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced that it will present a poster on SYNB8802, an
investigational Synthetic Biotic medicine for the treatment of
Enteric Hyperoxaluria (HOX), during the American Society
of Nephrology (ASN) Kidney Week, Oct. 22-25,
2020.
Title: Development of a Synthetic Biotic, SYNB8802, for the
Treatment of Enteric Hyperoxaluria
Poster #: PO0650
Synlogic will present the results of an effort to engineer
a Synthetic Biotic bacterial strain, SYNB8802, to
metabolize oxalate in the GI tract as a new treatment for enteric
hyperoxaluria. SYNB8802 is moving into human clinical
studies where it will be assessed for safety and
tolerability, strain kinetics, changes in plasma and urine
biomarkers of strain activity, and the potential to reduce
urinary oxalate.
Learn more about Synlogic's programs and pipeline by visiting
https://www.synlogictx.com/.
About Enteric Hyperoxaluria
Enteric
hyperoxaluria (HOX) is an acquired metabolic disorder caused by
increased absorption of dietary oxalate, which is present in many
common foods including leafy greens, nuts, and chocolate. Enteric
hyperoxaluria often occurs as a result of a primary insult to the
bowel, such as inflammatory bowel disease, Crohn's
disease, short bowel syndrome, or as a result of surgical
procedures such as Roux-en-Y bariatric weight-loss surgery.
Enteric hyperoxaluria results in dangerously high levels of
urinary oxalate, which causes progressive kidney damage, kidney
stone formation, and nephrocalcinosis. There are an estimated
250,000 patients with enteric hyperoxaluria in the United States. Enteric hyperoxaluria has
no approved treatment options.
About SYNB8802
SYNB8802 is an engineered
non-pathogenic strain of E. coli (Nissle), using Synlogic's
Synthetic Biotic platform, designed to consume oxalate in the GI
tract and lower urinary oxalate levels, potentially reducing kidney
damage due to enteric hyperoxaluria. SYNB8802 is administered
orally. SYNB8802 is currently undergoing IND-enabling studies.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
The company is also building a portfolio of partner-able assets in
immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials and availability of
clinical trial data. Actual results could differ materially from
those contained in any forward-looking statement as a result of
various factors, including: the uncertainties inherent in the
clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original
content:http://www.prnewswire.com/news-releases/synlogic-presents-preclinical-data-on-synb8802-for-enteric-hyperoxaluria-at-american-society-of-nephrology-asn-kidney-week-2020-301157555.html
SOURCE Synlogic, Inc.